Neupro (rotigotine)
- Region
- 🇪🇺 EU
- Active substance
- rotigotine
- Company
- UCB Pharma S.A.
- Status
- Authorised
- Therapeutic area
- Restless Legs Syndrome; Parkinson Disease
- CHMP opinion
- Thu 15 Dec 2005
- EU approval
- Wed 15 Feb 2006
- Application
- EMEA/H/C/000626
- ATC
- N04BC09
- Official record
- www.ema.europa.eu
Indication
Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations). Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Leganto Withdrawn · UCB Pharma S.A.
- 🇪🇺 Rotigotine Mylan Application withdrawn · Mylan S.A.S
Follow Neupro
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.